Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug

Core Viewpoint - Viking Therapeutics Inc's stock has increased by 10.1% to $24.42 following Pfizer's decision to halt the development of its weight-loss pill, creating a favorable environment for Viking's weight-loss drug candidates [1] Company Performance - Despite today's increase, VKTX is down 39.3% in 2025, having reached a 12-month low of $18.92 on April 9, and is down 65% year-over-year [2] Options Activity - Options trading is heavily focused on calls, with a 10-day call/put volume ratio of 14.71, indicating strong bullish sentiment, as over 16,000 calls have been traded today, which is six times the average intraday volume [3]